相关临床试验
472
58 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1885
进行中（未招募）
29
6.1%
已完成
232
49.1%
Enrolling By Invitation
7
1.5%
尚未招募
22
4.7%
招募中
63
13.3%
暂停
2
0.4%
终止
48
10.2%
Unknown
42
8.9%
撤回
27
5.7%
暂无批准数据
- A Nature study presents the first genomic analysis of eight Myotis bat species, linking longer lifespans to stronger immune defense and cancer-suppressing gene activity. - Cells from the little brown bat responded to lethal chemical damage by activating cell-death genes rather than DNA repair, mirroring the elephant's anti-cancer strategy. - Researchers found far more overlap than expected by chance between genes associated with bat longevity and genes involved in bat-virus interactions. - Myotis bats show unusual enrichment of genes interacting with DNA viruses such as herpesviruses, a pattern opposite to humans and other primates.
- Menopause triggers a profound "bioenergetic crisis" in the brain, with glucose metabolism dropping by approximately 20% in postmenopausal women compared to premenopausal women, according to research led by Roberta Brinton at the University of Arizona. - Brain imaging studies reveal white matter volume declines by roughly 10% during postmenopause, potentially as the brain turns to lipids as an alternative fuel source when estrogen plummets. - The menopausal transition may unmask neurological vulnerabilities, with two-thirds of Alzheimer's cases occurring in women and earlier menopause associated with greater risk. - Hormone replacement therapy can improve cognition during perimenopause, but timing is critical — protective effects are most evident when treatment begins within 10 years before the final menstrual period.
- University of Arizona researchers found four cannabis terpenes—geraniol, linalool, beta-caryophyllene, and alpha-humulene—produced significant pain relief in preclinical mouse models of fibromyalgia and post-operative pain. - Geraniol demonstrated the strongest analgesic effects, and all four compounds acted through the adenosine A2a receptor without producing THC-like psychoactive effects. - Fibromyalgia affects up to 5% of the global population and approximately 4 million U.S. adults, while roughly 310 million major surgeries are performed worldwide annually, underscoring the need for non-opioid alternatives. - The findings, published by John Streicher's lab and funded by NIH grant R01AT011517, suggest terpenes may represent a novel therapeutic class for chronic and pathological pain conditions.
- The University of Arizona will begin a double-blind, randomized Phase 3 clinical trial to evaluate whether rapamycin can improve resilience and immune function in older adults. - The six-year study is funded by $12 million in philanthropic support from alumnus R. Ken Coit and will test low-dose rapamycin in participants aged 65 and older. - Researchers will measure rapamycin's impact on physical function and frailty transition, as well as its ability to reduce IL-6 inflammatory markers associated with age-related diseases. - Previous studies have demonstrated that rapamycin can improve vaccine efficacy and oral health in older adults, making it a promising candidate for healthy aging interventions.
- University of Arizona researchers have identified a new molecule that could reverse opioid overdoses with longer-lasting effects than naloxone, potentially requiring only a single dose. - The experimental treatment addresses naloxone's 30-minute duration limitation and may be more effective against carfentanil, a synthetic opioid 100 times stronger than fentanyl. - Researchers aim to make the drug widely available within one to two years through expedited FDA approval, targeting Arizona's crisis where over five people die daily from opioid overdoses.
- A comprehensive meta-analysis of 53 studies involving over 8.4 million postmenopausal women found that starting hormone replacement therapy within five years of menopause onset reduces Alzheimer's disease risk by 32%. - Women who began hormone therapy at age 65 or older showed a 38% increased risk of developing Alzheimer's disease, particularly when treatment included progestin. - The findings suggest a critical window hypothesis where early hormone therapy may protect brain function during the neurological transition of menopause, but starting too late may be counterproductive. - Researchers emphasize that while the data is promising, more rigorous clinical trials are needed to establish definitive guidelines for hormone therapy timing and formulations.
- University of Arizona researchers developed Paclitaxome, a new nanovesicle formulation of paclitaxel that outperformed standard chemotherapy drugs Taxol and Abraxane in mouse models of triple-negative breast cancer and advanced pancreatic cancer. - The formulation chemically attaches paclitaxel to sphingomyelin to create nanovesicles that improve tumor delivery, extend circulation time, and reduce accumulation in healthy tissues like the liver and spleen. - Indian researchers created fluorescent nanoparticles coated with transferrin that selectively target cancer cells overexpressing transferrin receptors, releasing over 90% of paclitaxel over two days while sparing normal cells. - Both platforms demonstrate the potential for improved drug delivery systems that could reduce chemotherapy side effects while enhancing therapeutic efficacy across multiple cancer types.
- Octapharma's phase 3 trial of PANZYGA for pediatric acute-onset neuropsychiatric syndrome (PANS) missed its primary endpoint of reducing obsessive-compulsive symptoms measured by CY-BOCS score. - The study achieved statistical significance on the key secondary endpoint of Clinical Global Impression (CGI-I) score, showing clinically relevant improvement in overall disease burden (p-value = 0.017). - PANZYGA demonstrated a 31.1% mean improvement in CY-BOCS scores compared to 12.1% with placebo, though the difference was not statistically significant (p-value = 0.072). - The crossover analysis revealed continued symptom improvement in patients who initially received PANZYGA, suggesting sustained therapeutic effects from the immunoglobulin treatment.
- Researchers have discovered that levodopa-induced dyskinesia in Parkinson's patients involves a functional disconnection of the motor cortex from movement control. - A study on rats showed that ketamine can reduce dyskinesia by normalizing brain activity and partially restoring the motor cortex's ability to regulate movement. - Clinical trials are underway at the University of Arizona testing low-dose ketamine infusions for dyskinesia, with preliminary results showing promising outcomes. - The findings suggest that ketamine may offer a novel therapeutic approach by targeting the underlying neural mechanisms of dyskinesia rather than just managing symptoms.
